全文获取类型
收费全文 | 4101602篇 |
免费 | 279815篇 |
国内免费 | 10070篇 |
专业分类
耳鼻咽喉 | 57743篇 |
儿科学 | 130422篇 |
妇产科学 | 111156篇 |
基础医学 | 569109篇 |
口腔科学 | 117109篇 |
临床医学 | 375993篇 |
内科学 | 791173篇 |
皮肤病学 | 91334篇 |
神经病学 | 338975篇 |
特种医学 | 158702篇 |
外国民族医学 | 1438篇 |
外科学 | 610563篇 |
综合类 | 91194篇 |
现状与发展 | 6篇 |
一般理论 | 1721篇 |
预防医学 | 325696篇 |
眼科学 | 94894篇 |
药学 | 301783篇 |
102篇 | |
中国医学 | 7990篇 |
肿瘤学 | 214384篇 |
出版年
2018年 | 43844篇 |
2017年 | 33747篇 |
2016年 | 38369篇 |
2015年 | 43121篇 |
2014年 | 60704篇 |
2013年 | 92100篇 |
2012年 | 122391篇 |
2011年 | 129875篇 |
2010年 | 77879篇 |
2009年 | 74455篇 |
2008年 | 121871篇 |
2007年 | 129456篇 |
2006年 | 131201篇 |
2005年 | 126850篇 |
2004年 | 122244篇 |
2003年 | 117849篇 |
2002年 | 114682篇 |
2001年 | 187059篇 |
2000年 | 192544篇 |
1999年 | 163311篇 |
1998年 | 48490篇 |
1997年 | 43268篇 |
1996年 | 42906篇 |
1995年 | 41620篇 |
1994年 | 38636篇 |
1993年 | 36151篇 |
1992年 | 129757篇 |
1991年 | 125527篇 |
1990年 | 121334篇 |
1989年 | 117245篇 |
1988年 | 108362篇 |
1987年 | 106746篇 |
1986年 | 100819篇 |
1985年 | 96584篇 |
1984年 | 72642篇 |
1983年 | 62033篇 |
1982年 | 37358篇 |
1981年 | 33618篇 |
1979年 | 66754篇 |
1978年 | 47236篇 |
1977年 | 40023篇 |
1976年 | 37493篇 |
1975年 | 39597篇 |
1974年 | 47990篇 |
1973年 | 45811篇 |
1972年 | 43108篇 |
1971年 | 39923篇 |
1970年 | 37310篇 |
1969年 | 35275篇 |
1968年 | 32452篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
112.
V. Jenkins I. Solis-Trapala H. Payne M. Mason L. Fallowfield S. May L. Matthews S. Catt 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):99-107
Aims
Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.Material and methods
Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.Results
In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study.Conclusion
Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted. 相似文献113.
K.A. Lee M.T.A. Sharabiani D. Tumino J. Wadsley V. Gill G. Gerrard R. Sindhu M.N. Gaze L. Moss K. Newbold 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(6):385-390
Aims
To obtain an overview of the management and outcomes of children aged 18 years or younger diagnosed with differentiated thyroid carcinoma of follicular cell origin across the UK, by collecting and analysing data from the limited number of centres treating these patients. This multicentre data might provide a more realistic perspective than single-institution series.Materials and methods
Six centres submitted data extracted from historical records on patients aged 18 years or younger, diagnosed between 1964 and 2017. The univariate and multivariable Cox proportional hazard model was used to identify potential predictors of progression-free survival, using national data as a control.Results
Data on 166 patients were available for analysis. Females (74%) were predominant, and the age ranged from 3 to 19 years at diagnosis, mean 14.1 years. Nodal metastases were present in 51%; 12% had distant metastases. After surgery, 95% received radioactive iodine (39% on more than one occasion) and 4% received external beam radiotherapy. With a median follow-up duration of 5 years, 69% are alive with no evidence of disease; 20% are alive with a raised thyroglobulin level as the only evidence of residual disease; 6% have residual structural disease detectable on imaging; 2% have died, from cerebral metastases.Conclusion
Despite most patients having advanced disease at presentation, outcomes are very good. A national prospective registry should allow systematic collection of good-quality data and may facilitate research to further improve outcomes. 相似文献114.
Edward J.A. Harris Steven Kao Brian McCaughan Takashi Nakano Nobuyuki Kondo Rebecca Hyland Anna K. Nowak Nicholas H. de Klerk Fraser J.H. Brims 《Journal of thoracic oncology》2019,14(2):288-293
Introduction
Malignant pleural mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centers to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in unselected MPM patients using routinely collected clinical data. This study aimed to examine the performance of this CART model on a highly selected surgical population.Methods
Data were collected from subjects undergoing cytoreductive surgery for MPM from specialist centers in Hyõgo, Japan, and Sydney, Australia, between 1991 and 2016. The CART model was applied using the combination of clinical variables to stratify subjects into risk groups (1 through 4); survival characteristics were then compared.Results
Two hundred eighty-nine cases were included (205 from Australia, 84 from Japan). Overall median survival was 34.6 (interquartile range: 17.5–56.1) months; median age was 63.0 (interquartile range: 57.0–67.8) years, and 83.0% (n = 240) were male. There were no clinically meaningful differences between the two cohorts. Survival across the four risk groups was significantly different (p < 0.0001); the model stratified survival well with a Harrell's concordance statistic of 0.62 (95% confidence interval: 0.57–0.66) at 36 months. The group with the longest survival (median, 82.5 months) had: no weight loss, hemoglobin > 153 g/L and serum albumin > 43 g/L at time of referral to the surgical center.Conclusions
Using routinely available clinical variables, the CART model was able to stratify surgical patients into risk groups with statistically different survival characteristics with fair to good performance. Presence of weight loss, anemia, and low albumin should confer caution when considering surgical therapy for MPM. 相似文献115.
Annette E Hay Nicole Mittmann Michael Crump Matthew C Cheung Jessica Sleeth Judy Needham Mike Broekhoven Marina Djurfeldt Lois E Shepherd Ralph M Meyer Bingshu E Chen Joseph L Pater 《Current oncology (Toronto, Ont.)》2021,28(2):1153
In a prospective study, we sought to determine acceptability of linkage of administrative and clinical trial data among Canadian patients and Research Ethics Boards (REBs). The goal is to develop a more harmonized approach to data, with potential to improve clinical trial conduct through enhanced data quality collected at reduced cost and inconvenience for patients. On completion of the original LY.12 randomized clinical trial in lymphoma (), participants were invited to enrol in the Long-term Innovative Follow-up Extension (LIFE) component. Those consenting to do so provided comprehensive identifying information to facilitate linkage with their administrative data. We prospectively designed a global assessment of this innovative approach to clinical trial follow-up including rates of REB approval and patient consent. The pre-specified benchmark for patient acceptability was 80%. Of 16 REBs who reviewed the research protocol, 14 (89%) provided approval; two in Quebec declined due to small patient numbers. Of 140 patients invited to participate, 115 (82%, 95% CI 76 to 88%) from across 9 Canadian provinces provided consent and their full name, date of birth, health insurance number and postal code to facilitate linkage with their administrative data for long-term follow-up. Linkage of clinical trial and administrative data is feasible and acceptable. Further collaborative work including many stakeholders is required to develop an optimized secure approach to research. A more coordinated national approach to health data could facilitate more rapid testing and identification of new effective treatments across multiple jurisdictions and diseases from diabetes to COVID-19. NCT00078949相似文献
116.
Georg Hahn Sharon M. Lutz Julian Hecker Dmitry Prokopenko Michael H. Cho Edwin K. Silverman Scott T. Weiss Christoph Lange 《Genetic epidemiology》2021,45(1):82-98
locStra is an ‐package for the analysis of regional and global population stratification in whole‐genome sequencing (WGS) studies, where regional stratification refers to the substructure defined by the loci in a particular region on the genome. Population substructure can be assessed based on the genetic covariance matrix, the genomic relationship matrix, and the unweighted/weighted genetic Jaccard similarity matrix. Using a sliding window approach, the regional similarity matrices are compared with the global ones, based on user‐defined window sizes and metrics, for example, the correlation between regional and global eigenvectors. An algorithm for the specification of the window size is provided. As the implementation fully exploits sparse matrix algebra and is written in C++, the analysis is highly efficient. Even on single cores, for realistic study sizes (several thousand subjects, several million rare variants per subject), the runtime for the genome‐wide computation of all regional similarity matrices does typically not exceed one hour, enabling an unprecedented investigation of regional stratification across the entire genome. The package is applied to three WGS studies, illustrating the varying patterns of regional substructure across the genome and its beneficial effects on association testing. 相似文献
117.
118.
119.
120.
Gregory Lazarian Shanye Yin Elisa ten Hacken Tomasz Sewastianik Mohamed Uduman Alba Font-Tello Satyen H. Gohil Shuqiang Li Ekaterina Kim Heather Joyal Leah Billington Elizabeth Witten Mei Zheng Teddy Huang Mariano Severgnini Valerie Lefebvre Laura Z. Rassenti Catherine Gutierrez Catherine J. Wu 《Cancer cell》2021,39(3):380-393.e8